RASTEN试验中低分子肝素依从性及其对生存的影响
RASTEN是一项多中心随机III期试验,探讨低分子肝素联合标准治疗能否改善小细胞肺癌生存。本研究用Heparin Red法和抗Xa活性法检测258例患者血浆LMWH水平,ROC分析显示依从率分别为68%和85%。依从亚组与对照组相比均无生存获益(抗Xa法HR 1.26,95%CI 0.95-1.67,P=0.105;Heparin Red法HR 1.19,95%CI 0.89-1.60,P=0.248),排除了依从性差导致RASTEN阴性结果的可能。
要点
- Heparin Red法可识别高概率依从LMWH治疗的患者。
- 依从LMWH的患者未显示生存获益,排除依从性差解释阴性结果。
- 抗Xa法与Heparin Red法均可区分LMWH组与对照组。
核心结论
- LMWH依从亚组未显示生存获益,排除了RASTEN阴性结果由依从性差所致的可能。
研究设计与样本
- RASTEN为多中心随机III期试验,评估LMWH联合标准治疗能否改善小细胞肺癌生存。
- 采用Heparin Red法和抗Xa活性法检测258例患者血浆LMWH水平。
主要发现
- 两种方法均可区分LMWH组与对照组及因血栓接受治疗剂量LMWH的患者。
- ROC分析得出依从率:抗Xa法85%,Heparin Red法68%。
- 依从亚组与对照组相比无生存获益:抗Xa法HR 1.26(95%CI 0.95-1.67,P=0.105),Heparin Red法HR 1.19(95%CI 0.89-1.60,P=0.248)。
临床怎么用
- Heparin Red法可定义高概率依从LMWH治疗的患者,有待前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coagulation activation is a hallmark of cancer, and anticoagulants have shown tumour-inhibiting properties. However, recent trials have failed to demonstrate improved survival with low-molecular-weight heparin (LMWH) in cancer populations. This has raised the question of suboptimal adherence as a possible explanation for the lack of benefit. Still, there is no standardised method to directly monitor LMWH in patient plasma. Here, we directly determine LMWH levels in patients using the Heparin Red assay to objectively assess adherence and how this associates with the patient outcome in the RASTEN trial. METHODS: RASTEN is a multicentre, randomised phase III trial investigating if the addition of LMWH to standard therapy can improve survival in small-cell lung cancer. LMWH was measured in plasma (N = 258) by the Heparin Red assay and compared with the anti-factor Xa (anti-FXa) activity assay. RESULTS: Both methods could differentiate patients in the LMWH arm from the control arm and patients receiving therapeutic LMWH owing to thrombosis. Receiver Operating Characteristic (ROC) analysis yielded adherence rates of 85% for anti-FXa and 68% for Heparin Red. No survival benefits were found in the adherent subgroup compared with the control arm (hazard ratio [HR]: 1.26; 95% confidence interval [CI]: 0.95-1.67; P = 0.105 and HR: 1.19; 95% CI: 0.89-1.60; P = 0.248 for anti-FXa and Heparin Red, respectively). Heparin Red could define patients with high probability of adherence to LMWH treatment, which warrants prospective studies for further validation. Our finding that the LMWH-adherent subpopulation did not show improved survival excludes that the negative outcome of RASTEN was due to poor adherence.
引用
- Gezelius E, Bendahl PO, Gonçalves de Oliveira K, et al. Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN). Eur J Cancer. 2019. PMID: 31326730. doi:10.1016/j.ejca.2019.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。